ABY-271 / Affibody - LARVOL DELTA

Theranostic Pair of Affibody Molecules Targeting HER2 Expressing Cancer (SNMMI 2025) - "The theranostic pair targets a different HER2 epitope compared to trastuzumab or pertuzumab, allowing them to be administered concomitantly. Tezatabep matraxetan has demonstrated clinical utility in early trials with breast cancer patients, underscoring the unmet need for improved diagnostics that overcome the limitations of biopsy-based HER2 analysis. In preclinical studies, [177Lu]Lu-ABY-271 demonstrated a favorable biodistribution profile and potent antitumor effect, which was further enhanced when combined with trastuzumab. A first-in-human study of [177Lu]Lu-ABY-271 is currently under way with early results anticipated during 2025."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

Theranostic Pair of Affibody Molecules Targeting HER2 Expressing Cancer (SNMMI 2025) - "The theranostic pair targets a different HER2 epitope compared to trastuzumab or pertuzumab, allowing them to be administered concomitantly. Tezatabep matraxetan has demonstrated clinical utility in early trials with breast cancer patients, underscoring the unmet need for improved diagnostics that overcome the limitations of biopsy-based HER2 analysis. In preclinical studies, [177Lu]Lu-ABY-271 demonstrated a favorable biodistribution profile and potent antitumor effect, which was further enhanced when combined with trastuzumab. A first-in-human study of [177Lu]Lu-ABY-271 is currently under way with early results anticipated during 2025."

Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2